Esculetin (at a concentration of 50 mM) was effective against HepG2 liver cancer cells, by binding to three potential targets (phosphoglycerate kinase 2 (PGK2), glycerol-3-phosphate dehydrogenase (GPD2) and glucose-6-phosphate isomerase (GPI)). The gene discussed is GPD2; the disease is liver cancer.